Pages that link to "Q36395293"
Jump to navigation
Jump to search
The following pages link to A framework for quantifying net benefits of alternative prognostic models (Q36395293):
Displaying 12 items.
- Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy (Q30563774) (← links)
- An assessment of the relationship between clinical utility and predictive ability measures and the impact of mean risk in the population (Q33926791) (← links)
- Circulating, imaging, and genetic biomarkers in cardiovascular risk prediction (Q36037541) (← links)
- Evaluating hospital performance based on excess cause-specific incidence (Q36311241) (← links)
- Testing for improvement in prediction model performance. (Q36763246) (← links)
- Personalized Evaluation of Biomarker Value: A Cost-Benefit Perspective (Q37079999) (← links)
- A framework for evaluating markers used to select patient treatment (Q37282240) (← links)
- Modeling the costs and long-term health benefits of screening the general population for risks of cardiovascular disease: a review of methods used in the literature. (Q37306497) (← links)
- Prognostic models for stable coronary artery disease based on electronic health record cohort of 102 023 patients. (Q37676925) (← links)
- Developing novel prognostic biomarkers for multivariate fracture risk prediction algorithms (Q38025330) (← links)
- Characterizing expected benefits of biomarkers in treatment selection (Q38914707) (← links)
- Identifying optimal biomarker combinations for treatment selection via a robust kernel method (Q42182239) (← links)